הלוואות ואשראי לטווח ארוך של החברה: carismatx.com (CARM)

Carisma Therapeutics (CARM) maintains production facilities for genetically modified macrophages in Pennsylvania, while drug manufacturing is delegated to US CDMO plants, as reflected in this price chart capturing trading dynamics, where the indicator stands at 0.00. The technology stack is based on robotic cell culture management to eliminate human error. Meanwhile, the business faces a liquidity shortage and the depletion of reserves due to costly trials.

For Carisma Therapeutics (CARM), the volume of the firm's long-term borrowings demonstrates financial stability amid aggressive hiring of macrophage engineering experts and the implementation of its R&D strategy. This indicator aggregates all liabilities with a maturity of more than one year, allowing investors to assess the debt load and risks of equity dilution, which is critical for evaluating the solvency of a biotechnology business.